Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified infliximab induction in pediatric Crohn's disease
NL-OMON51805Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease and inflammatory bowel disease (IBD), sponsored by Erasmus MC. Primary endpoint: Therapeutic infliximab trough level at week 12 without treatment escalation. Started Aug 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON51805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51805.